Shots:
- The US FDA has granted 2 FTDs to TT125-802 for NSCLC: one for EGFR exon 19 deletion or exon 21 L858R mutation pts progressing after EGFR inhibitors, & another for KRAS G12C-mutated pts progressing after KRAS G12C inhibitors
- TT125-802 is being assessed in P-I trial to evaluate its safety, tolerability, PK, & efficacy in pts with advanced solid tumors
- TT125-802 is an oral CBP/p300 inhibitor targeting cancer survival & resistance pathways, which showed superior efficacy & safety in P-I trial as presented at ASCO’25, with clinical monotx. activity in solid tumors & no thrombocytopenia
Ref: TOLREMO Therapeutics | Image: TOLREMO Therapeutics | Press Release
Related News:- Foresee Pharmaceuticals’ Camcevi ETM Receives the US FDA Approval for Advanced Prostate Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
